Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 1
2021 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.
Defining pre-symptomatic amyotrophic lateral sclerosis.
Benatar M, Turner MR, Wuu J. Benatar M, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):303-309. doi: 10.1080/21678421.2019.1587634. Epub 2019 Mar 20. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 30892087 Free PMC article. Review.
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.
Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR; First International Pre-Symptomatic ALS Workshop. Benatar M, et al. Brain. 2022 Mar 29;145(1):27-44. doi: 10.1093/brain/awab404. Brain. 2022. PMID: 34677606 Free PMC article.
A roadmap to ALS prevention: strategies and priorities.
Benatar M, Goutman SA, Staats KA, Feldman EL, Weisskopf M, Talbott E, Dave KD, Thakur NM, Al-Chalabi A. Benatar M, et al. J Neurol Neurosurg Psychiatry. 2023 May;94(5):399-402. doi: 10.1136/jnnp-2022-330473. Epub 2023 Jan 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36690429 Free PMC article. No abstract available.
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.
McMillan CT, Wuu J, Rascovsky K, Cosentino S, Grossman M, Elman L, Quinn C, Rosario L, Stark JH, Granit V, Briemberg H, Chenji S, Dionne A, Genge A, Johnston W, Korngut L, Shoesmith C, Zinman L; Canadian ALS Neuroimaging Consortium (CALSNIC); Kalra S, Benatar M. McMillan CT, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):517-526. doi: 10.1080/21678421.2022.2039713. Epub 2022 Mar 7. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 35253557 Free PMC article.
Neurofilaments in pre-symptomatic ALS and the impact of genotype.
Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. Benatar M, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):538-548. doi: 10.1080/21678421.2019.1646769. Epub 2019 Aug 21. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31432691 Free PMC article.
12 results